Project Grant R56HL174856
Award Date
9/20/24
Completion Date
8/31/25
Dollars Obligated
$547K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Denton, TX 76203, USA
Similar Awards
This Project Grant award of $248,999 from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) supports research by Washington University to elucidate the mechanisms of cardiovascular toxicity associated with tyrosine kinase inhibitor (TKI) cancer treatments. The research aims to leverage patient-derived induced pluripotent stem cells to model TKI-induced vascular dysfunction and identify candidate compounds that can mitigate these adverse cardiovascular...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) is focused on conducting definitive (GLP) toxicity and toxicology studies for a novel small molecule therapy to protect against cardiotoxicity in triple negative breast cancer (TNBC) patients. The $1,000,000 award will support the development and commercialization of this novel, safe, and effective therapy that synergizes with anthracyclines, such...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop a flexible bioelectronic microarchitecture that integrates a capillary-like delivery network and a tissue-like sensing network to improve cardiac tissue engineering. The $488,026 award supports the creation of a system that can efficiently deliver media and provide real-time physiological feedback to enhance the development of...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $642,454.00 to The Ohio State University to develop an artificial intelligence-based system for predicting the risk of cardiotoxicity in breast cancer patients undergoing anti-tumor therapies. The project aims to complement electronic health record data with multimodal data collected through wearable sensors and a conversational chatbot to create an improved risk prediction model....
This federal Project Grant award, totaling $753,813 and provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research), supports research to develop novel machine learning techniques for predicting cardiovascular outcomes in patients with clonal hematopoiesis of indeterminate potential (CHIP). The key goals are to use cardiac MRI imaging and genomic data to: 1) Develop a machine learning model to accurately identify CHIP patients and predict their risk...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) at the National Institutes of Health provides $167,864 to The Leland Stanford Junior University to investigate risk stratification and outcomes across the spectrum of cardiotoxicity from immune checkpoint inhibitor cancer therapies. The study aims to: 1) retrospectively examine cardiac and oncologic outcomes associated with immune checkpoint inhibitor cardiotoxicity based on...
This Project Grant award of $726,408 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) will fund research to define the role of endothelial TFEB in mitigating cardiovascular toxicity induced by cancer therapies. The award recipient, the University of Cincinnati, will leverage its expertise in endothelial cell biology and transgenic mouse models to explore how modulating the TFEB pathway can protect against...
This Project Grant award of $275,956 from the National Science Foundation's (NSF) Computer and Information Science and Engineering (CISE) program aims to develop an engineered cyber-physical system that combines advanced biological models with artificial intelligence methods for predictive, automated screening of anti-cancer drugs and optimization of their dosing. The key products and services to be delivered under this award include: 1) Adoption of 3D bioprinting to generate vascularized ductal...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $717,246 to The Leland Stanford Junior University (Stanford University) to investigate the molecular mechanisms underlying cardiovascular toxicity induced by the cancer drug carfilzomib. The goal is to elucidate the role of pathogenic alternative splicing events in smooth muscle cells and endothelial cells, using a humanized multiple...
This $697,952 Project Grant awarded by the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to investigate the molecular mechanisms underlying osimertinib-induced cardiac dysfunction and explore potential therapeutic targets. The key objectives are to: 1) Examine the association between the downregulation of myosin light chain kinase 3 (MYLK3) and osimertinib-induced contractile dysfunction, and assess whether overexpressing MYLK3 can prevent this...